NASDAQ:ALKS Alkermes (ALKS) Stock Forecast, Price & News $29.10 +0.08 (+0.28%) (As of 09/25/2023 ET) Add Compare Share Share Today's Range$28.70▼$29.3150-Day Range$27.17▼$31.9752-Week Range$21.75▼$33.71Volume1.26 million shsAverage Volume1.46 million shsMarket Capitalization$4.85 billionP/E Ratio51.05Dividend YieldN/APrice Target$33.33 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Alkermes MarketRank™ ForecastAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside14.5% Upside$33.33 Price TargetShort InterestBearish5.69% of Shares Sold ShortDividend StrengthN/ASustainability-1.17Upright™ Environmental ScoreNews Sentiment0.82Based on 2 Articles This WeekInsider TradingN/AProj. Earnings Growth56.38%From $0.94 to $1.47 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.20 out of 5 starsMedical Sector378th out of 961 stocksPharmaceutical Preparations Industry163rd out of 453 stocks 2.3 Analyst's Opinion Consensus RatingAlkermes has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $33.33, Alkermes has a forecasted upside of 14.5% from its current price of $29.10.Amount of Analyst CoverageAlkermes has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.69% of the outstanding shares of Alkermes have been sold short.Short Interest Ratio / Days to CoverAlkermes has a short interest ratio ("days to cover") of 5.5.Change versus previous monthShort interest in Alkermes has recently increased by 16.03%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAlkermes does not currently pay a dividend.Dividend GrowthAlkermes does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAlkermes has received a 60.90% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for physical health", "Antipsychotics", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Alkermes is -1.17. Previous Next 2.1 News and Social Media Coverage News SentimentAlkermes has a news sentiment score of 0.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Alkermes this week, compared to 4 articles on an average week.Search InterestOnly 5 people have searched for ALKS on MarketBeat in the last 30 days. This is a decrease of -38% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Alkermes to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Alkermes insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.76% of the stock of Alkermes is held by insiders.Percentage Held by Institutions95.21% of the stock of Alkermes is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Alkermes are expected to grow by 56.38% in the coming year, from $0.94 to $1.47 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Alkermes is 51.05, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 121.48.Price to Earnings Ratio vs. SectorThe P/E ratio of Alkermes is 51.05, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 135.11.Price to Book Value per Share RatioAlkermes has a P/B Ratio of 4.58. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Alkermes (NASDAQ:ALKS) StockAlkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in the fields of neuroscience and oncology in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of product candidates in development for neurological disorders and cancer. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence, and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.Read More ALKS Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALKS Stock News HeadlinesSeptember 18, 2023 | americanbankingnews.comAlkermes plc (NASDAQ:ALKS) Receives Average Rating of "Moderate Buy" from AnalystsSeptember 17, 2023 | americanbankingnews.comAlkermes plc (NASDAQ:ALKS) Sees Large Increase in Short InterestSeptember 25, 2023 | Legacy Research (Ad)Watch SHOCKING Footage of AI Facility with Ties to Elon MuskI recently traveled more than 3,000 miles and shot this video outside what could end up being Elon Musk’s biggest secret. Most people don’t know about this facility, but it could be the most important AI project in the world. What’s happening inside these walls is so important that our government has declared it a matter of national security.September 15, 2023 | finance.yahoo.comAlkermes (ALKS) Stock Moves -0.84%: What You Should KnowSeptember 13, 2023 | realmoney.thestreet.comFor Potential Alkermes Buyers, There's a Key Price Level to WatchSeptember 11, 2023 | finanznachrichten.deAlkermes plc: Alkermes Presents Clinical and Real-World Data at 36th Annual Psych CongressSeptember 11, 2023 | finance.yahoo.comAlkermes Presents Clinical and Real-World Data at 36th Annual Psych CongressSeptember 7, 2023 | uk.style.yahoo.comAlkermes (ALKS) Recently Broke Out Above the 50-Day Moving AverageSeptember 25, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...September 7, 2023 | finance.yahoo.comAlkermes Announces Launch of 6th Annual Alkermes Pathways Research Awards(R) ProgramSeptember 7, 2023 | finance.yahoo.comAlkermes Announces Launch of 6th Annual Alkermes Pathways Research Awards® ProgramSeptember 6, 2023 | finance.yahoo.comHere's Why Alkermes (ALKS) is a Strong Momentum StockAugust 31, 2023 | finance.yahoo.comAlkermes Announces Recipients of 2023 Alkermes Inspiration Grants(R) ProgramAugust 31, 2023 | finanznachrichten.deAlkermes plc: Alkermes Announces Recipients of 2023 Alkermes Inspiration Grants® ProgramAugust 31, 2023 | finance.yahoo.comAlkermes Announces Recipients of 2023 Alkermes Inspiration Grants® ProgramAugust 30, 2023 | stocknews.com3 Best Biotech Stocks for Growth in SeptemberAugust 30, 2023 | msn.comAlkermes to grant Teva license for generic Vivitrol, settles litigationAugust 30, 2023 | finanznachrichten.deAlkermes plc: Alkermes Announces Settlement With Teva Related to VIVITROL® Patent LitigationAugust 30, 2023 | finance.yahoo.comAlkermes Announces Settlement With Teva Related to VIVITROL® Patent LitigationAugust 29, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: BridgeBio Pharma (BBIO) and Alkermes (ALKS)August 28, 2023 | markets.businessinsider.comAlkermes Honors Women's Equality DayAugust 25, 2023 | stocknews.com3 Biotech Stocks to Buy This Month and BeyondAugust 25, 2023 | msn.comAlkermes falls as activist holder Sarissa Capital cuts stakeAugust 25, 2023 | finance.yahoo.comWhy Is Alkermes (ALKS) Down 9% Since Last Earnings Report?August 25, 2023 | stocknews.comIs Now the Time to Buy Into Moderna, Inc. (MRNA)?August 25, 2023 | seekingalpha.comAlkermes: A Complicated Story Right NowAugust 24, 2023 | msn.comLybalvi: Weighing In Light, But Tipping Alkermes' ScalesSee More Headlines Receive ALKS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alkermes and its competitors with MarketBeat's FREE daily newsletter. Email Address ALKS Company Calendar Last Earnings7/26/2023Today9/25/2023Next Earnings (Estimated)11/01/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:ALKS CUSIPG0176710 CIK1520262 Webwww.alkermes.com Phone(531) 772-8000Fax781-890-0524Employees2,280Year Founded1987Price Target and Rating Average Stock Price Forecast$33.33 High Stock Price Forecast$40.00 Low Stock Price Forecast$28.00 Forecasted Upside/Downside+14.5%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)$0.57 Trailing P/E Ratio51.05 Forward P/E Ratio30.96 P/E GrowthN/ANet Income$-158,270,000.00 Net Margins7.04% Pretax Margin7.03% Return on Equity2.33% Return on Assets1.27% Debt Debt-to-Equity Ratio0.23 Current Ratio2.87 Quick Ratio2.48 Sales & Book Value Annual Sales$1.11 billion Price / Sales4.36 Cash Flow$0.25 per share Price / Cash Flow114.99 Book Value$6.35 per share Price / Book4.58Miscellaneous Outstanding Shares166,560,000Free Float158,631,000Market Cap$4.85 billion OptionableOptionable Beta0.60 Social Links 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. Richard F. Pops (Age 61)Chairman & CEO Comp: $2.3MMr. Iain Michael Brown (Age 54)Sr. VP & CFO Comp: $867.75kMr. Blair C. Jackson (Age 50)Exec. VP & COO Comp: $1.05MMr. David Joseph Gaffin (Age 51)Exec. VP, Chief Legal Officer, Chief Compliance Officer & Sec. Comp: $1.08MDr. Craig C. Hopkinson M.D. (Age 55)Exec. VP of R&D and Chief Medical Officer Comp: $1.12MDr. Floyd E. Bloom M.D. (Age 86)Founder Mr. Thomas HarveyChief Information Officer & Sr. VP of ITMs. Sandra CoombsSr. VP of Corp. Affairs & Investor RelationsMr. Michael J. Landine (Age 69)Sr. VP of Corp. Devel. & Chief Risk Officer Mr. Stephen SchiavoSr. VP of HRMore ExecutivesKey CompetitorsImmunoGenNASDAQ:IMGNIonis PharmaceuticalsNASDAQ:IONSAmicus TherapeuticsNASDAQ:FOLDMadrigal PharmaceuticalsNASDAQ:MDGLDynavax TechnologiesNASDAQ:DVAXView All CompetitorsInsiders & InstitutionsTucker Asset Management LLCBought 1,420 shares on 9/8/2023Ownership: 0.001%Wolverine Trading LLCBought 11,300 shares on 8/23/2023Ownership: 0.000%Virginia Retirement Systems ET ALBought 569,800 shares on 8/22/2023Ownership: 0.342%Teachers Retirement System of The State of KentuckyBought 10,351 shares on 8/21/2023Ownership: 0.016%Osaic Holdings Inc.Sold 4,673 shares on 8/21/2023Ownership: 0.007%View All Insider TransactionsView All Institutional Transactions ALKS Stock - Frequently Asked Questions Should I buy or sell Alkermes stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Alkermes in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ALKS shares. View ALKS analyst ratings or view top-rated stocks. What is Alkermes' stock price forecast for 2023? 6 analysts have issued twelve-month price targets for Alkermes' stock. Their ALKS share price forecasts range from $28.00 to $40.00. On average, they expect the company's stock price to reach $33.33 in the next year. This suggests a possible upside of 14.5% from the stock's current price. View analysts price targets for ALKS or view top-rated stocks among Wall Street analysts. How have ALKS shares performed in 2023? Alkermes' stock was trading at $26.13 on January 1st, 2023. Since then, ALKS shares have increased by 11.4% and is now trading at $29.10. View the best growth stocks for 2023 here. Are investors shorting Alkermes? Alkermes saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 9,480,000 shares, an increase of 16.0% from the August 15th total of 8,170,000 shares. Based on an average daily volume of 1,710,000 shares, the short-interest ratio is presently 5.5 days. View Alkermes' Short Interest. When is Alkermes' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023. View our ALKS earnings forecast. How were Alkermes' earnings last quarter? Alkermes plc (NASDAQ:ALKS) posted its quarterly earnings results on Wednesday, July, 26th. The company reported $0.38 EPS for the quarter, beating the consensus estimate of $0.28 by $0.10. The business had revenue of $617.40 million for the quarter, compared to the consensus estimate of $572.57 million. Alkermes had a net margin of 7.04% and a trailing twelve-month return on equity of 2.33%. What ETFs hold Alkermes' stock? ETFs with the largest weight of Alkermes (NASDAQ:ALKS) stock in their portfolio include AdvisorShares Psychedelics ETF (PSIL), Subversive Mental Health ETF (SANE), iShares Neuroscience and Healthcare ETF (IBRN), Horizon Kinetics Medical ETF (MEDX), ALPS Medical Breakthroughs ETF (SBIO), First Trust NYSE Arca Biotechnology Index Fund (FBT), Invesco Biotechnology & Genome ETF (PBE) and Putnam BioRevolution ETF (SYNB). What guidance has Alkermes issued on next quarter's earnings? Alkermes updated its FY23 earnings guidance on Wednesday, July, 26th. The company provided earnings per share (EPS) guidance of $1.34-$1.57 for the period, compared to the consensus estimate of $1.12. The company issued revenue guidance of $1.55-$1.68 billion, compared to the consensus revenue estimate of $1.48 billion. What is Richard F. Pops' approval rating as Alkermes' CEO? 119 employees have rated Alkermes Chief Executive Officer Richard F. Pops on Glassdoor.com. Richard F. Pops has an approval rating of 84% among the company's employees. What other stocks do shareholders of Alkermes own? Based on aggregate information from My MarketBeat watchlists, some companies that other Alkermes investors own include Gilead Sciences (GILD), Netflix (NFLX), Pfizer (PFE), NVIDIA (NVDA), AbbVie (ABBV), Starbucks (SBUX), Intel (INTC), Johnson & Johnson (JNJ) and Tesla (TSLA). What is Alkermes' stock symbol? Alkermes trades on the NASDAQ under the ticker symbol "ALKS." Who are Alkermes' major shareholders? Alkermes' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (10.14%), State Street Corp (3.54%), Hardman Johnston Global Advisors LLC (3.46%), Renaissance Technologies LLC (3.10%), Geode Capital Management LLC (2.00%) and Bank of New York Mellon Corp (1.59%). Insiders that own company stock include Blair Curtis Jackson, Cato T Laurencin, Christian Todd Nichols, Craig C Hopkinson, Craig C Hopkinson, David Joseph Gaffin, David W Anstice, Emily Peterson Alva, Iain Michael Brown, Michael J Landine, Nancy Wysenski, Richard F Pops, Shane Cooke and Wendy L Dixon. View institutional ownership trends. How do I buy shares of Alkermes? Shares of ALKS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Alkermes' stock price today? One share of ALKS stock can currently be purchased for approximately $29.10. How much money does Alkermes make? Alkermes (NASDAQ:ALKS) has a market capitalization of $4.85 billion and generates $1.11 billion in revenue each year. The company earns $-158,270,000.00 in net income (profit) each year or $0.57 on an earnings per share basis. How many employees does Alkermes have? The company employs 2,280 workers across the globe. Does Alkermes have any subsidiaries? The following companies are subsidiares of Alkermes: Rodin Therapeutics.Read More How can I contact Alkermes? Alkermes' mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE, DUBLIN L2, DUBLIN 4. The official website for the company is www.alkermes.com. The company can be reached via phone at (531) 772-8000, via email at investor_relations@alkermes.com, or via fax at 781-890-0524. This page (NASDAQ:ALKS) was last updated on 9/25/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alkermes plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.